AAV9 hIDS Gene Therapy With Immunosuppression for CNS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies for Hunter syndrome, such as Elaprase®, do not effectively cross the blood-brain barrier, failing to address neurocognitive and behavioral issues in severe cases of Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome.
Innovation Solution
A replication-deficient adeno-associated virus (rAAV) is used to deliver a functional human iduronate-2-sulfatase (hIDS) gene directly to the CNS, accompanied by an immunosuppressive regimen to enhance therapeutic efficacy, particularly through intrathecal injection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy (Elaprase) is administered to treat MPS II, then peripheral enzyme deficiency is corrected, but the therapy cannot cross the blood-brain barrier and neurocognitive symptoms remain untreated
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors as intermediaries to deliver the hIDS gene across the blood-brain barrier. The AAV capsid serves as a mediator that facilitates CNS penetration, which the enzyme replacement therapy cannot achieve alone. This resolves the contradiction by introducing a viral vector intermediary that enables brain delivery while the enzyme itself addresses the peripheral deficiency.
Solution Approach 2:
The treatment is segmented into two distinct components: (1) enzyme replacement therapy for peripheral tissue correction, and (2) AAV-mediated gene therapy for CNS correction. This segmentation allows each component to optimize for its specific target tissue, resolving the contradiction between peripheral efficacy and CNS penetration.
2Adaptability or versatility
If AAV vector is used to deliver hIDS gene to CNS, then neurocognitive symptoms are addressed, but immune response may reduce therapeutic efficacy
Solution Approach 1:
The patent implements preliminary immunosuppressive treatment before AAV vector administration. This preliminary action suppresses the immune system in advance to prevent neutralizing antibody formation and cellular immunity against the AAV vector, thereby ensuring the vector can deliver the hIDS gene effectively to the CNS without being eliminated by the immune response.
Solution Approach 2:
The immunosuppressive regimen acts as a preliminary anti-action against the potential harmful immune response. By administering immunosuppressants before and during AAV treatment, the patent preemptively counteracts the immune system's tendency to reject the viral vector, protecting the therapeutic efficacy.
3Reliability
If immunosuppressive regimen is combined with AAV therapy, then viral vector acceptance is improved, but treatment complexity increases
Solution Approach 1:
The patent employs systemic immunosuppressive agents that serve multiple functions: they suppress overall immune activity to prevent vector rejection, reduce inflammation, and create a favorable environment for transgene expression. This multi-functionality justifies the added complexity by providing broader therapeutic benefits beyond just improving gene delivery acceptance.
Data Source
AI summary
A co-therapeutic regimen comprising AAV9-mediated intrathecal/intracisternal and/or systemic delivery of an expression cassette containing a hIDS gene and two or more immunosuppressants is provided herein. Also provided are methods and kits containing these vectors and compositions useful for treating Hunter syndrome and the symptoms associated with Hunter syndrome.